Revisiting Methodologies for In Vitro Preparations of Advanced Glycation End Products

Appl Biochem Biotechnol. 2022 Jun;194(6):2831-2855. doi: 10.1007/s12010-022-03860-5. Epub 2022 Mar 8.

Abstract

Chronic elevation of sugar and oxidative stress generally results in development of advanced glycation end products (AGEs) in diabetic individuals. Accumulation of AGEs in an individual can give rise to the activation of several pathways that will ultimately lead to various complications. Such AGEs can also be prepared in an in vitro environment. For an in vitro preparation of advanced glycation end products (AGEs), proteins, lipids, or nucleic acids are generally required to be incubated with reducing sugars at a physiological temperature or higher depending upon the protocol optimized for its preparation. Certain other factors are also optimized and added to the buffer to hasten its preparation or alter the properties of prepared AGEs. Through this review, we intend to highlight the various studies related to the experimental procedures for the preparation of different types of AGEs. In addition, we present the comparative study of methodologies optimized for the preparation of AGEs.

Keywords: Advanced glycation end products (AGEs); Cardiovascular diseases; Glycation; Maillard reaction.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus*
  • Glycation End Products, Advanced* / metabolism
  • Humans
  • Oxidative Stress
  • Receptor for Advanced Glycation End Products / metabolism

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products